New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
|
|
- Grant Pope
- 5 years ago
- Views:
Transcription
1 New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
2 Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase III trials 5-10 year horizon: Ongoing and imminent phase IIB/C trials The Universal Regimen vs. Precision Medicine 2
3 WHO Target regimen profiles for TB treatment (2016) Aim: - To assist drug regimen developers in identifying important regimen features and aligning these with patient and programmatic needs at country level Three separate target profiles: - Rifampicin-susceptible TB (DS-TB) - Rifampicin-resistant TB (RR-TB) - Pan-susceptible TB ( Pan-TB ) 3
4 Pan-susceptible TB and The Universal Regimen A regimen for Pan-TB (a.k.a. The Universal Regimen) is intended to treat both DS-TB and RR-TB - Doesn t include a rifamycin (or isoniazid) - Disease that is susceptible to drugs in the regimen Very attractive to drug developers as it unifies treatment of TB leading to a bigger market share - Completely new regimen with no pre-existing resistance 4
5 Regimen development strategies Global numbers of patients, millions (% of total) Drugs likely to have more side effects Lower hurdle for efficacy improvements Rifamycin-containing regimen Substitution of 1-3 old drugs to shorten therapy Completely new regimen without a rifamycin May or may not include older drugs DR-TB 0.5m (5%) DS-TB 9.5m (95%) Pan-TB 10m (99+%) 5
6 Regimen development strategies Global numbers of patients, millions (% of total) Drugs likely to have more side effects Potentially a lower hurdle for efficacy improvements Rifamycin-containing regimen Substitution of 1-3 old drugs to shorten therapy Completely new regimen without a rifamycin May or may not include older drugs DR-TB 0.5m (5%) DS-TB 9.5m (95%) Pan-TB 10.0m (99%) Approach for bedaquiline, delamanid and pretomanid 6 Regulatory approval Historically an easier pathway for regulatory approval for a new drug May no longer be so smooth
7 Regimen development strategies Global numbers of patients, millions (% of total) Drugs likely to have more side effects Potentially a lower hurdle for efficacy improvements Rifamycin-containing regimen Substitution of 1-3 old drugs to shorten therapy Completely new regimen without a rifamycin May or may not include older drugs DR-TB 0.5m (5%) DS-TB 9.5m (95%) Pan-TB 10.0m (99%) Likely more favored approach today for a new regimen Regulatory approval 7
8
9 Ongoing phase III trials for DS-TB and Pan-TB New regimens in 1-3 years? Moxifloxacin NIRT Study 31/A5349 High-dose rifapentine High-dose rifampicin RIFASHORT TRUNCATE-TB For the purposes of this presentation, a Phase III trial is one with at least 6 months post-treatment follow-up which is powered for some sort of comparison using long-term outcomes. New drugs STAND SimpliciTB 9
10 10 1. NIRT Moxifloxacin ICMR National Institute for Research in TB (NIRT), Chennai, India Previous randomized trials Regimen 3-month 3RHZO 4-month 3RHZO/1HR 5-month 3RHZO/2HR 4-month 2RHZO/2HR Total patients 529 randomized Relapse n(%) 83 7 (8%) 81 3 (4%) 86 2 (2%) (13%) Narayanan P. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc. 2002;49: randomized 2(RHZE) 3 /4(HR) 3 2(MHRZ) 3 /2(MHR) 3 2(GHRZ) 3 /2(GHR) 3 R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol M Moxifloxacin G Gatifloxacin O Ofloxacin X 3 Thrice-weekly Jawahar MS et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030 Comment: Concerns about the conduct and analysis of this study 3b02-495e-adbf-1204ff6e27df
11 1. NIRT Moxifloxacin ICMR National Institute for Research in TB (NIRT), Chennai, India Previous phase III trials with moxifloxacin (REMoxTB) R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol M Moxifloxacin G Gatifloxacin O Ofloxacin X 3 Thrice-weekly 1931 randomized 2RHZE/4HR 2RHZM/2MHR 2RMZE/2MR Gillespie SH et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med. 2014;371(17):
12 1. NIRT Moxifloxacin ICMR National Institute for Research in TB (NIRT), Chennai, India Sites South India R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol M Moxifloxacin X 3 Thrice-weekly Sample size: 1371 Recruitment: May 2007 Oct 2016 Results: 2019 Newly diagnosed pulmonary DS-TB, HIV negative CTRI Registration: PROVCTRI/2008/091/ Control 2(RHZE) 3 /4(RH) 3 3-month 3RHZEM 4-month 2RHZEM/2RHM 4-month 2RHZEM/2(RHM) 3 4-month 2RHZEM/2(RHEM) 3 12
13 1. NIRT Moxifloxacin ICMR National Institute for Research in TB (NIRT), Chennai, India Preliminary results (not peer-reviewed) ( - Faster culture conversion with moxifloxacin 94% vs 77% (p < 0.001) - Improved end of treatment outcomes with moxifloxacin 91% - 93% vs 86% (p < 0.05) - 84 (7%) recurrences to date across all arms 13
14 2. Study 31/A5349 Rifapentine and Moxifloxacin CDC TB Trials Consortium (TBTC) / NIH AIDS Clinical Trials Group (ACTG) Phase II experience with rifapentine randomized 334 randomized Dose for Study 31 / A5349: 1200mg with food Dorman SE et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015;191(3): Savic RM et al. Defining the Optimal Dose of Rifapentine for Pulmonary Tuberculosis: Exposure-Response Relations From Two Phase 2 Clinical Trials. Clin Pharmacol Ther
15 2. Study 31/A5349 Rifapentine and Moxifloxacin CDC TB Trials Consortium (TBTC) / NIH AIDS Clinical Trials Group (ACTG) Sites: Global Sample size: 2516 ClinicalTrials.gov Registration: NCT Recruitment: Jan 2016 Oct 2018 Results: Q R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol M Moxifloxacin P Rifapentine Control 2RHZE/4RH Newly diagnosed pulmonary DS- TB 4-month 2PHZM/2PHM 4-month 2PHZE/2PH 15
16 2. Study 31/A5349 Rifapentine and Moxifloxacin CDC TB Trials Consortium (TBTC) / NIH AIDS Clinical Trials Group (ACTG) 16
17 3. RIFASHORT High-dose Rifampicin INTERTB & St. George s, University of London Phase II experience with rifampicin R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol Q SQ109 M Moxifloxacin R 35 R 35 mg/kg 365 randomized Boeree MJ et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39-49 Svensson EM et al. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018;67(1):
18 3. RIFASHORT High-dose Rifampicin INTERTB & St. George s, University of London Sites: Sample size: 654 Botswana, Uganda, Nepal, Guinea, Peru Recruitment: Feb 2017 Q Results: Q Newly diagnosed pulmonary DS- TB, HIV negative ClinicalTrials.gov Registration: NCT R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol Control (R 10mg/kg) 2RHZE/4RH 4-month (R 1200mg) 2RHZE/2RH 4-month (R 1800mg) 2RHZE/2RH 18
19 4. TRUNCATE-TB Old and new drugs University College London (UCL) & National University of Singapore (NUS) A trial to evaluate a novel strategy, not just novel regimens 19
20 4. TRUNCATE-TB Old and new drugs University College London (UCL) & National University of Singapore (NUS) Sites: Sample size: 900 Singapore, Thailand, Philippines ClinicalTrials.gov Registration: NCT Recruitment: Q Q Results: Q R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol Lz Linezolid C Clofazimine Lv Levofloxacin B Bedaquiline R 35 R 35 mg/kg Control 2RHZE/4RH 2/3-month R 35 HZELz Newly diagnosed pulmonary DS-TB 2/3-month R 35 HZEC 2/3-month PHZELv 2/3-month BHZELz 20
21 5. STAND & SimpliciTB Global Alliance for TB Drug Development Phase II experience with pretomanid (Pa) 240 randomized Bacterial decline in solid culture media over 8 weeks Pa 100 MZ HRZE 181 randomized Regimen Population % neg on liquid cultures at 8 weeks % neg on solid cultures at 8 weeks Pa 200 MZ BPaZ DS-TB 66% 89% BPaZ DS-TB 75%* 84% BPaMZ BPaMZ HRZE control MDR-TB Z-sensitive MDR-TB Z-resistant 96%* 100%* 78%* 95%* DS-TB 51% 86% R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol B Bedaquiline Pa Pretomanid Bacterial decline in liquid culture media over 8 weeks 21
22 5. STAND Old and new drugs Global Alliance for TB Drug Development Sites: Sample size: Global 284 (1200 planned) ClinicalTrials.gov Registration: NCT Recruitment: Q Q Results: 2019 Newly diagnosed pulmonary DS-TB R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol M - Moxifloxacin Pa Pretomanid Control 2RHZE/4RH 6-month 6Pa 200 MZ 4-month 4Pa 200 MZ 4-month 4Pa 100 MZ 22
23 6. SimpliciTB Old and new drugs Global Alliance for TB Drug Development & PanACEA Sites: Global Sample size: 300 ClinicalTrials.gov Registration: NCT Recruitment: Q Q Results: Q R Rifampicin H Isoniazid Z Pyrazinamide E Ethambutol M - Moxifloxacin Pa Pretomanid B - Bedaquiline Control 2RHZE/4RH Newly diagnosed pulmonary DS- TB 4-month BPaMZ 23
24 New regimens for DS-TB 1-3 year horizon (estimated) 4-month PaMZ 3/4-month M 4-month P or MP 4-month BPaMZ B Bedaquiline C Clofazimine E Ethambutol H Isoniazid Lv Levofloxacin Lz Linezolid M - Moxifloxacin P Rifapentine Pa Pretomanid R Rifampicin Z Pyrazinamide 2/3-month R 35 Lz, R 35 C, PLv, BLz 4-month R 1200/1800mg
25 Ongoing or imminent phase IIB/C trials for DS-TB and Pan-TB New regimens in 5-10 years? Phase IIC trials (long-term outcomes) - CLO-FAST (ACTG A5362) 3/4-month regimens with clofazimine and high-dose rifapentine - PanACEA STEP 4-month regimens with various combinations of sutezolid, high-dose pyrazinamide and high-dose rifampicin (40mg/kg?) - TBTC CRUSH-TB Phillips PP, et al. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med. 2016;14(1):51. 4-month regimens with bedaquiline/pyrazinamide backbone 25
26 Ongoing or imminent phase IIB/C trials for DS-TB and Pan-TB New regimens in 5-10 years? Platform phase IIC trials (multi-arm multi-sponsor) 26
27 Ongoing or imminent phase IIB/C trials for DS-TB and Pan-TB New regimens in 5-10 years? Platform phase IIC trials (multi-arm multi-sponsor) STAMPEDE Trial in prostate cancer (thanks to Matt Sydes) 27
28 The Universal Regimen and Precision Medicine One-Size-Fits-All, or The Right Regimen for the Right Patient? 28
29 The Universal Regimen and Precision Medicine One-Size-Fits-All, or The Right Regimen for the Right Patient? Imperial MZ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature Medicine
30 Stratified medicine and the treatment of TB TBTC CURE-TB (Protocol in development) Strategy 1: Baseline Risk Markers Strategy 2: Baseline/On Treatment Markers 30
31
TB New Drugs, Shorter Courses
TB New Drugs, Shorter Courses Brian Chong John Hunter Hospital, Newcastle NSW Talk supervisor: Chris Coulter Disclosures Unfortunately none 1 Current Situation In 2013, Australia had: 1,263 notified TB
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationMultidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool)
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool) DOTS + and LTBI New drugs for TB and the challenge of resistance talk plan 1. Epidemiology 2. Treatment 3. The MDRTB
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More informationEffects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
More informationClinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationTreatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
More informationMDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
More informationTHE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
More informationMDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationTreatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas May 6 9, 2014 MDR/XDR TB Barbara Seaworth, MD May 9, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial relationships
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationDR-TB PATIENT IDENTITY CARD
Ministry of Health Community Development Gender Elderly and Children National Tuberculosis and Leprosy Programme DR-TB 02 DR-TB Treatment Unit: DR-TB PATIENT IDENTITY CARD DR-TB Reg. Number: Date of registration:
More informationThe role of moxifloxacin in tuberculosis therapy
CLINICAL YEAR IN REVIEW TUBERCULOSIS The role of moxifloxacin in tuberculosis therapy Stephen H. Gillespie Affiliation: School of Medicine, University of St Andrews, St Andrews, UK. Correspondence: Stephen
More informationMDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
More informationSummary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing PRELIMINARY 4 th Annual GLI meeting 17 April 2012 Fuad Mirzayev Laboratories, Diagnostics and Drug Resistance unit, Stop
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More informationUniversity of Groningen. Tuberculosis and its sequelae Akkerman, Onno
University of Groningen Tuberculosis and its sequelae Akkerman, Onno IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationMDR TB AND CASE STUDIES
MDR TB AND CASE STUDIES Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Seattle, CITC Clinical Intensive June 15, 2018 Slide
More informationTreatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
More informationQuality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products
Quality of 2 nd line medicines for tuberculosis Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Case studies in medicines for tuberculosis Outline: Statistics
More informationThe New England Journal of Medicine THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY
THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY KEMAL TAHAOĞLU, M.D., TÜLAY TÖRÜN, M.D., TÜLIN SEVIM, M.D., GÜLIZ ATAÇ, M.D., ALTAN KIR, M.D., LEVENT KARASULU, M.D., IPEK ÖZMEN, M.D., AND NILÜFER
More informationXDR TB: The Laboratory s Dilemma vs The Clinician s Dilemma
XD TB: The Laboratory s Dilemma vs The Clinician s Dilemma Barbara J. Seaworth, MD, FIDSA, FACP, Heartland National TB Center, San Antonio, TX Kenneth Jost, Jr., M(ASCP) Laboratory Services Section, Texas
More informationTreatment of Nontuberculous Mycobacterial Infections (NTM)
Treatment of Nontuberculous Mycobacterial Infections (NTM) Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory
More informationPractical. Walk through New Survival Guide
Many faces of TB: Drug resistant it ttbs Survival lgid Guide v3 P B L Ch G Sh t L T P. Barry, L. Chen, G. Schecter, L. True Curry International TB Center/CTCA April 20, 2016 Real case Practical Walk through
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GRANUPAS, gastro-resistant granules 30 sachets with a calibrated measuring spoon (CIP: 34009 278 801
More informationSterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2003, p. 653 657 Vol. 47, No. 2 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.2.653 657.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationCreating a global community for clinical drug repurposing and development. Leonard Sacks Center for drug evaluation and research FDA
Creating a global community for clinical drug repurposing and development Leonard Sacks Center for drug evaluation and research FDA Neglected tropical diseases 1) Repurposing and developing new drugs 2)
More informationOnline data supplement
Online data supplement Title: Fluoroquinolone therapy for the prevention of multi-drug resistant tuberculosis in contacts: a cost-effectiveness analysis Authors: Gregory J Fox Olivia Oxlade Dick Menzies
More informationOverview of antibiotic combination issues.
Overview of antibiotic combination issues. Professor Anthony Coates St George s, University of London Founder, CSO, Helperby Therapeutics Ltd The most serious problem is Carbapenem resistant Gram-negatives
More informationTB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History
TB Grand Rounds MDR-TB: Management of Adverse Drug Reactions Reynard J. McDonald, M.D. September 18, 2007 Patient History This 30 y/o H/M was born in Ecuador and immigrated to the US in 2001 On 11-22-05
More informationNew antituberculosis drugs and regimens
New antituberculosis drugs: from clinical trial to programmatic use Gina Gualano, 1 Susanna Capone, 2 Alberto Matteelli, 2 Fabrizio Palmieri 1 1 Respiratory Infectious Diseases Unit, National Institute
More informationLinezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Eur Respir J 2012; 39: 956 962 DOI: 10.1183/09031936.00076811 CopyrightßERS 2012 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India R.
More informationDrug resistant TB: The role of the laboratory
Drug resistant TB: The role of the laboratory 26 Oct 2012 Andrew Whitelaw NHSLS / UCT TB lab functions: Outline Resistance testing Genotypic Phenotypic Which tests are done when, and why Reporting of
More informationDr. Angela Huttner, FMH Division of Infectious Diseases Geneva University Hospitals 5 December
The PIRATE PROJECT: a Point-of-care, Informatics-based Randomized, controlled trial for decreasing over-utilization of Antibiotic ThErapy in Gram-negative Bacteremia Dr. Angela Huttner, FMH Division of
More informationSection 6.2.4: Antituberculosis Medicines Application for moving streptomycin to complementary list
Section 6.2.4: Antituberculosis Medicines Application for moving streptomycin to complementary list Stop TB Department World Health Organization Summary According to the recent guideline published in 2010
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationThe challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases
J Bras Pneumol. 2015;41(6):554-559 http://dx.doi.org/10.1590/s1806-37562015000000299 CASE REPORT The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of
More informationTreatment of Slowly Growing NTM Infections
Treatment of Slowly Growing NTM Infections Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory Committee Insmed
More informationIntroduction of Bedaquiline in the Philippines
Introduction of Bedaquiline in the Philippines 24th PhilCAT Annual Convention Crown Plaza Hotel August 18,2107 Vivian S. Lofranco, MD., PHSAE National Clinical Coordinator, BDQ MDR-TB is highly contagious
More informationNon-Tuberculous Mycobacterial Pulmonary Disease Diagnosis and Management Jakko van Ingen, MD, PhD
Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) 1 Radbound University Nihmegen Medical Center Milestones in NTM research 1980s: Nodular bronchiectatic lung disease Lady Windermere syndrome 1882-1890
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationAntimicrobial Resistance (2013)
Antimicrobial Resistance (2013) In the second half of 2013, the NIHR issued a call for research into the evaluation of public health measures, health care interventions and health services to reduce the
More informationPOPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH DRUG- RESISTANT TUBERCULOSIS
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH DRUG- RESISTANT TUBERCULOSIS Emmanuel Chigutsa 1, Sandra Meredith 1, Lubbe Wiesner 1, Nesri Padayatchi 2, Joe
More informationDr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sharanjit Dhoot Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationAMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationMultidrug-resistant Tuberculosis
Multidrug-resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive September 2016
More informationMultidrug resistant Tuberculosis
Multidrug resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive October 018 Objectives
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationReceived 19 November 2008; returned 10 January 2009; revised 20 February 2009; accepted 24 February
Journal of Antimicrobial Chemotherapy (2009) 63, 1173 1178 doi:10.1093/jac/dkp096 Advance Access publication 28 March 2009 Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationCase 1 and Case 2. Case 1 3/23/2016
Case 1 and Deidra D. Parrish, MD, MPH&TM Nashville Metro Public Health Dept TB Symposium March 30, 2016 Case 1 27 yo Indian woman came to the US to join her husband three months prior to clinic visit.
More informationDuration of antibiotic therapy:
Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant
More informationTuberculosis in 2017: Searching for new solutions in the face of new challenges
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
More informationCommonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities
Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we
More informationORIGINAL INVESTIGATION. Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease
ORIGINAL INVESTIGATION Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease Pinky D. Gaba, MD; Connie Haley, MD, MPH; Marie R. Griffin, MD,
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More informationMoxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis William J. Burman, Stefan Goldberg, John L. Johnson, Grace Muzanye, Melissa Engle, Ann W. Mosher, Shurjeel Choudhri,
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationPalpasa Kansakar, Geeta Shakya, Nisha Rijal, Basudha Shrestha
In-vitro resistance of Salmonella Typhi and Paratyphi A raises concern on the use of older fluroquinolones in the empiric treatment of enteric fever in Nepal Palpasa Kansakar, Geeta Shakya, Nisha Rijal,
More informationExtensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital
MAJOR ARTICLE Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital Christie Y. Jeon, 1,2,a Soo Hee Hwang, 5,a Jin Hong
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationTb : Recent recommendation. Dr.Ketan Shah
Tb : Recent recommendation Dr.Ketan Shah Tbc : Clinician If you think It is easy to diagnose : u r not good clinician It is difficult to diagnose :U r not alone doctor to think this 6/22/2015 Ketan Shah
More informationDrug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016
Drug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016 Drug- Resistant TB: De1initions Mono- resistant: Resistance to a single drug Poly-
More informationMGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience
MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience Dr Johan Van Wyk MB.Ch.B, M.Med (Clin Path) Clinical Pathologist ibhayi Region, Eastern Cape GWYNETH PALTROW SHAKESPEARE IN LOVE 1998 PORT
More informationApril 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee
More informationImpact of a Standardized Protocol to Address Outbreak of Methicillin-resistant
Impact of a Standardized Protocol to Address Outbreak of Methicillin-resistant Staphylococcus Aureus Skin Infections at a large, urban County Jail System Earl J. Goldstein, MD* Gladys Hradecky, RN* Gary
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationCritical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary
Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical
More informationFluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis
INT J TUBERC LUNG DIS 20(12):S42 S47 Q 2016 The Union http://dx.doi.org/10.5588/ijtld.16.0117 MDR-TB TRIALS LANDSCAPE SUPPLEMENT Fluoroquinolones for the treatment and prevention of multidrug-resistant
More informationEradiaction of Resistant Organisms:
Eradiaction of Resistant Organisms: Can we do it and does it help? Noah Lechtzin, MD; MHS Director, Adult CF Program Outline Evidence resistant organisms are bad MRSA, B cepacia, Pseudomonas, Fungal infections
More informationThe Future of Antibiotic Alternatives
The Future of Antibiotic Alternatives @Elanco #feedthe9 Grady Bishop Sr. Director Market Access Elanco 1 The Global Landscape our WHY 2 Today s 3 Food Security Realities 3 The Protein Gap 4 The impact
More informationHosted by Dr. Benedetta Allegranzi, WHO Patient Safety Agency A Webber Training Teleclass
The History of Medicine Antimicrobial Resistance Issues Worldwide and the WHO Approach to Combat It Carmem Lúcia Pessoa-Silva, MD, PhD Health Security and Environment Cluster, WHO HQ, Geneva Hosted by
More informationCurrent Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.80.2.143 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2017;80:143-152 Current Status of Fluoroquinolone Use for Treatment of Tuberculosis
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationTitle: Resistance to fluoroquinolones and second line injectable drugs: impact on MDR TB outcomes
ERJ Express. Published on October 25, 2012 as doi: 10.1183/09031936.00134712 Title: Resistance to fluoroquinolones and second line injectable drugs: impact on MDR TB outcomes Authors: D. Falzon, N. Gandhi,
More informationAND MISCONCEPTIONS IN THE MANAGEMENT OF SEPSIS
MYTHS AND MISCONCEPTIONS IN THE MANAGEMENT OF SEPSIS SEPSISMADE EASY SURVIVINGSEPSIS COOKBOOK SEPSIS ISAPIE MERVYN SINGER BLOOMSBURY INSTITUTE OF INTENSIVE CARE MEDICINE UNIVERSITY COLLEGE LONDON, UK DISCUSSION
More informationMultidrug resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
Original Article Multidrug resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai Zarir F. Udwadia, Gautam Moharil Department of Pulmonology,
More information: "INFECTION CONTROL: WHAT'S COMING IN 2017?" LISA THOMAS RN-BC STATE TRAINING COORDINATOR OFFICE OF LONG TERM CARE
: "INFECTION CONTROL: WHAT'S COMING IN 2017?" LISA THOMAS RN-BC STATE TRAINING COORDINATOR OFFICE OF LONG TERM CARE OBJECTIVES REVIEW STATISTICS ASSOCIATED WITH OLDER ADULTS AND THEIR RISK OF INFECTIONS
More informationRifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
MAJOR ARTICLE Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis H. M. J. Nijland, 1,3,a R. Ruslami, 4,a A. Juwono Suroto, 5 D. M. Burger, 1,3 B. Alisjahbana, 6 R. van
More information